MicroRNA‐26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin‐6‐Stat3 pathway

Xin Yang, Lei Liang, Xiao‐Fei Zhang, Hu‐Liang Jia, Yi Qin, Xu‐Chao Zhu, Xiao‐Mei Gao, Peng Qiao, Yan Zheng, Yuan‐Yuan Sheng, Jin‐Wang Wei, Hai‐Jun Zhou, Ning Ren, Qing‐Hai Ye, Qiong‐Zhu Dong, Lun‐Xiu Qin – 6 February 2013 – Down‐regulation of microRNA‐26a (miR‐26a) is associated with poor prognosis of hepatocellular carcinoma (HCC), but its functional mechanism in HCC remains unclear. In this study, we investigated the roles of miR‐26a in tumor growth and metastasis of HCC and found that miR‐26a was frequently down‐regulated in HCC tissues.

Interaction of signal transducer and activator of transcription 3 polymorphisms with hepatitis B virus mutations in hepatocellular carcinoma

Jiaxin Xie, Yuwei Zhang, Qi Zhang, Yifang Han, Jianhua Yin, Rui Pu, Qiuxia Shen, Wei Lu, Yan Du, Jun Zhao, Xue Han, Hongwei Zhang, Guangwen Cao – 5 February 2013 – Hepatitis B virus (HBV) mutations and signal transducer and activator of transcription 3 (STAT3) activation are closely associated with hepatocellular carcinoma (HCC). However, single nucleotide polymorphisms (SNPs) of STAT3 have not been implicated in HCC susceptibility. This study was designed to evaluate the effect of STAT3 SNPs and their interactions with HBV mutations on HCC risk.

Wnt5a signaling mediates biliary differentiation of fetal hepatic stem/progenitor cells in mice

Kei Kiyohashi, Sei Kakinuma, Akihide Kamiya, Naoya Sakamoto, Sayuri Nitta, Hideto Yamanaka, Kouhei Yoshino, Junko Fujiki, Miyako Murakawa, Akiko Kusano‐Kitazume, Hiromichi Shimizu, Ryuichi Okamoto, Seishin Azuma, Mina Nakagawa, Yasuhiro Asahina, Naoki Tanimizu, Akira Kikuchi, Hiromitsu Nakauchi, Mamoru Watanabe – 5 February 2013 – The molecular mechanisms regulating differentiation of fetal hepatic stem/progenitor cells, called hepatoblasts, which play pivotal roles in liver development, remain obscure.

Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load

Stuart C. Gordon, Zahary Krastev, Andrzej Horban, Jörg Petersen, Jan Sperl, Phillip Dinh, Eduardo B. Martins, Leland J. Yee, John F. Flaherty, Kathryn M. Kitrinos, Vinod K. Rustgi, Patrick Marcellin – 30 January 2013 – We evaluated the antiviral response of patients with chronic hepatitis B (CHB) who had baseline high viral load (HVL), defined as having hepatitis B virus (HBV) DNA ≥9 log10 copies/mL, after 240 weeks of tenofovir disoproxil fumarate (TDF) treatment.

Faldaprevir combined with pegylated interferon alfa‐2a and ribavirin in treatment‐naïve patients with chronic genotype1 HCV: SILEN‐C1 trial

Mark S. Sulkowski, Tarik Asselah, Jacob Lalezari, Peter Ferenci, Hugo Fainboim, Barbara Leggett, Fernando Bessone, Stefan Mauss, Jeong Heo, Yakov Datsenko, Jerry O. Stern, George Kukolj, Joseph Scherer, Gerhard Nehmiz, Gerhard G. Steinmann, Wulf O. Böcher – 28 January 2013 – Faldaprevir (BI 201335) is a potent, hepatitis C virus (HCV) NS3/4A protease inhibitor with pharmacokinetic properties supportive of once‐daily (QD) dosing.

Subscribe to